2024
Conservative versus liberal oxygen therapy for intensive care unit patients: meta-analysis of randomized controlled trials
Li X, Dai B, Hou H, Zhao H, Wang W, Kang J, Tan W. Conservative versus liberal oxygen therapy for intensive care unit patients: meta-analysis of randomized controlled trials. Annals Of Intensive Care 2024, 14: 68. PMID: 38668955, PMCID: PMC11052962, DOI: 10.1186/s13613-024-01300-7.Peer-Reviewed Original ResearchIntensive care unit patientsLiberal oxygen therapyConservative oxygen therapyIntensive care unitRandomized controlled trialsHospital length of stayLength of stayOxygen therapyControlled trialsClinical outcomesHospital lengthMeta-analysis of randomized controlled trialsClinical outcomes of ICU patientsIntensive care unit length of stayIntensive care unit lengthOutcomes of ICU patientsCochrane Central Register of Controlled TrialsMeta-analysisCentral Register of Controlled TrialsMethodsWe systematically searched PubMedMechanical ventilation supportRegister of Controlled TrialsOutcomes of intensive care unitCochrane Central RegisterSystematically searched PubMedComparison between high-flow nasal cannula and conventional oxygen therapy in COVID-19 patients: a systematic review and meta-analysis
Wang J, Peng Y, Dai B, Hou H, Zhao H, Wang W, Tan W. Comparison between high-flow nasal cannula and conventional oxygen therapy in COVID-19 patients: a systematic review and meta-analysis. Therapeutic Advances In Respiratory Disease 2024, 18: 17534666231225323. PMID: 38230522, PMCID: PMC10798115, DOI: 10.1177/17534666231225323.Peer-Reviewed Original ResearchConceptsAcute hypoxemic respiratory failureHigh-flow nasal cannulaConventional oxygen therapyCOVID-19-related acute hypoxemic respiratory failureIntensive care unitHospital length of stayInvasive mechanical ventilationLength of stayIntensive care unit settingCOVID-19 patientsIntubation rateNasal cannulaMechanical ventilationOxygen therapyRatio of arterial oxygen partial pressure to fractional inspired oxygenHospital lengthArterial oxygen partial pressure to fractional inspired oxygenEfficacy of high-flow nasal cannulaIntensive care unit length of stayControlled trialsSystematic reviewRespiratory support strategiesIntensive care unit lengthHypoxemic respiratory failureMortality rate
2022
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Mustard C, Kelly J, team H. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e48-e49. PMID: 36456403, DOI: 10.1016/j.eururo.2022.11.006.Peer-Reviewed Original ResearchReply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Kelly J, team H. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e29-e30. PMID: 36272948, DOI: 10.1016/j.eururo.2022.10.009.Peer-Reviewed Original Research
2019
Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
Cox E, Saramago P, Kelly J, Porta N, Hall E, Tan W, Sculpher M, Soares M. Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. Clinical Genitourinary Cancer 2019, 18: e418-e442. PMID: 32144049, PMCID: PMC7427321, DOI: 10.1016/j.clgc.2019.12.004.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeNon-muscle-invasive bladder cancerMuscle-invasive bladder cancerProgression to muscle-invasive bladder cancerQuality of lifePatients' health-related quality of lifePatients' health-related qualityBladder cancerHealth-related qualityEQ-5D-3LGeneralized estimating equationsUK unit costsRandomized controlled trialsHRQoL decrementNon-muscle-invasive bladder cancer patientsHRQoLHealthcare costsHRQOL effectsLimited evidenceControlled trialsEstimating equationsTMN classificationClinical eventsAverage costRecurrence
2018
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Tan W, Panchal A, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths T, Page T, Hodgson D, Datta S, Billingham L, Kelly J. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology 2018, 75: 63-71. PMID: 30274699, DOI: 10.1016/j.eururo.2018.09.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerDisease-free survival timeCarcinoma in situBacillus Calmette-GuerinSecond-line therapyTreatment armsComplete responseOpen-labelNo significant differenceBladder cancerCourse of bacillus Calmette-GuerinNon-muscle-invasive bladder cancer patientsBacillus Calmette-Guerin failuresCarcinoma in situ patientsStandard second-line therapyBacillus Calmette-Guerin therapyRecurrence of non-muscle-invasive bladder cancerStandard of care treatmentControlled trialsPapillary bladder lesionsPhase III randomised controlled trialMedian follow-upBladder cancer outcomesSignificant differenceOutcome measuresIntravesical device-assisted therapies for non-muscle-invasive bladder cancer
Tan W, Kelly J. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nature Reviews Urology 2018, 15: 667-685. PMID: 30254383, DOI: 10.1038/s41585-018-0092-z.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerElectromotive drug administrationDevice-assisted therapiesBladder cancerHyperthermic chemotherapyDevice-assisted treatmentsIntravesical adjuvant treatmentHigh-risk diseaseResults of randomized trialsRisk of recurrenceRisk of progressionAlternative to BCGEffective treatment optionSingle-arm study designBladder cancer diagnosisBCG failureRandomized controlled trialsMaintenance regimensAdjuvant treatmentPatient cohortTreatment optionsRandomized trialsDrug AdministrationControlled trialsClinical guidelines
2017
PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL
Tan W, Buckley L, Devall A, Loubiére L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths L, Page T, Hodgson D, Datta S, Billingham L, Kelly J. PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL. Journal Of Urology 2017, 197: e367-e368. DOI: 10.1016/j.juro.2017.02.881.Peer-Reviewed Original Research665 Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial
Tan W, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths L, Page T, Hodgson D, Datta S, Bilingham L, Kelly J. 665 Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial. European Urology Open Science 2017, 16: e1156-e1157. DOI: 10.1016/s1569-9056(17)30720-0.Peer-Reviewed Original Research
2016
Robotic Assisted Radical Cystectomy with Extracorporeal Urinary Diversion Does Not Show a Benefit over Open Radical Cystectomy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Tan W, Khetrapal P, Tan W, Rodney S, Chau M, Kelly J. Robotic Assisted Radical Cystectomy with Extracorporeal Urinary Diversion Does Not Show a Benefit over Open Radical Cystectomy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. PLOS ONE 2016, 11: e0166221. PMID: 27820855, PMCID: PMC5098822, DOI: 10.1371/journal.pone.0166221.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyOpen radical cystectomyMeta-analysis of randomised controlled trialsExtracorporeal urinary diversionRandomised controlled trialsRadical cystectomyUrinary diversionPerioperative morbidityBladder cancerLack of Level I evidenceRobot-assisted radical cystectomy groupsPositive lymph node statusOutcomes of robot-assisted radical cystectomySystematic reviewControlled trialsOpen radical cystectomy patientsEfficacy of robot-assisted radical cystectomyInclusion criteriaPositive surgical marginsLymph node statusLymph node yieldMeta-analysisLevel I evidenceIntracorporeal urinary diversionWell-designed trials